Monopar Therapeutics stock drops almost 4% after earnings beat followed by downgrade to 'sell'

Traders Union
All News
Stocks
Monopar slides 3.61% today on selloff

Highlights

Monopar Therapeutics posted a quarterly loss per share of $0.46, outperforming consensus estimates by $0.41 but triggering a downgrade to 'sell.'
JPMorgan Chase & Co. marginally increased its stake in Monopar Therapeutics during Q2, now holding 1,921 shares.
Technical indicators signal a strong, overbought uptrend, but sharp intraday volatility and downside pressure raise short-term pullback risk with key support at $100.5 and resistance at $107.5.

Analyst downgrade follows earnings beat as institutional stake rises

Monopar Therapeutics reported a quarterly loss per share of ($0.46), surpassing analysts' consensus estimates by $0.41. This release was followed by an analyst downgrade from 'hold' to 'sell' in a report published Sunday. During the second quarter, JPMorgan Chase & Co. increased its stake in the company by 1,821 shares, now holding a total of 1,921 shares.

Anton Kharitonov, expert at Traders Union, highlights Monopar’s recent 3.61% drop and the immediate impact of the analyst downgrade. He notes that the technical overbought conditions coincide with heightened selling pressure near $100.5 support, which he sees as fragile after a weak session. The impressive outperformance on earnings did little to shift market sentiment. Kharitonov questions the sustainability of current bullish momentum given excessive technical readings and limited institutional accumulation. "The risk of a deeper pullback is significant, and I would urge caution for anyone considering buying at these levels."

Viktoras Karapetjanc, expert at Traders Union, believes Monopar Therapeutics maintains its bullish structure despite the recent decline. He sees the robust technical trend and JPMorgan’s increased stake as positive signals for further growth. Karapetjanc points out that the current consolidation phase opens multiple trading setups and that momentum remains on the side of buyers. "Breakout potential above $107.5 is high, and I expect the bullish trend to be rewarded in the coming sessions."

Parshwa Turakhiya, analyst, views today’s action as a test of sentiment following mixed signals from earnings and the analyst downgrade. He notes strong volatility and overbought technicals are amplifying short-term risk. Turakhiya emphasizes near-term trading opportunities around $100.5 support and $107.5 resistance. "Intraday setups favor active traders, but I would watch for a momentum reversal if $100.5 fails to hold."

Overbought momentum collides with volatility as buying wanes

Monopar Therapeutics is trading well above its 20-day, 50-day, and 200-day moving averages at $83.5332, $69.6256, and $69.5132, respectively, reflecting a bullish structure across all timeframes. The near-term ceiling sits at $107.5, with immediate support at $100.5, and the alignment between the 50-day and 200-day moving averages further confirms the prevailing bullish trend. Momentum conditions remain strong, indicated by a bullish MACD and an Average Directional Index (ADX) above 37, signaling robust trend strength. The Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI) all flag overbought territory, suggesting heightened risk of a pullback. Bull/Bear Power (BBP) is elevated, confirming buyers dominate intraday momentum, but also signals an overbought condition. The Awesome Oscillator further supports bullish momentum. Despite opening with a downside gap of about 2.38%, the stock is currently near session lows at $102.75, after declining 3.61% or $3.85. Intraday volatility stands at 6.97%. The tone for today reflects pronounced selling pressure after the open, in line with the overbought signals, suggesting caution.

Earlier, analysts noted that Monopar Therapeutics was exhibiting strong bullish momentum supported by robust technical indicators and sustained buying pressure. The current pullback and analyst downgrade introduce fresh downside risk, making the $100.5 support level critical to monitor for any potential shift in trend.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.